Archives
Mubritinib (TAK 165): Selective HER2 Inhibitor and Mitoch...
Mubritinib (TAK 165): Selective HER2 Inhibitor and Mitochondrial Complex I Modulator
Executive Summary: Mubritinib (TAK 165) exhibits high in vitro specificity for HER2 (IC50 ~6 nM) with minimal activity against EGFR, FGFR, PDGFR, or non-receptor kinases (APExBIO, product page). Recent peer-reviewed evidence demonstrates Mubritinib's primary cellular effect is potent inhibition of mitochondrial complex I, not direct HER2 binding in cellular contexts (Stephenson et al., 2020). Mubritinib’s solubility profile (≥76.9 mg/mL in DMSO) and chemical stability at -20°C make it suitable for diverse in vitro workflows. Its molecular structure contains a 1,3-nitrogen triazole motif critical for mitochondrial toxicity and anti-proliferative effects. These insights are essential for accurate experimental design and interpretation in HER2-driven cancer and metabolism research.
Biological Rationale
Mubritinib (TAK 165) was developed to selectively inhibit the HER2/ErbB2 receptor, a receptor tyrosine kinase overexpressed in certain breast and gastric cancers (see prior review). HER2 activation drives cell proliferation, survival, and metastasis via the PI3K/AKT and MAPK pathways. Targeted HER2 inhibition is a validated strategy for anti-cancer therapy, reducing tumor growth and improving survival in HER2-positive models. Mubritinib’s high in vitro HER2 selectivity (IC50 ~6 nM) positioned it as a reference compound for dissecting HER2-dependent signaling mechanisms (APExBIO). Recent studies, however, have revealed that Mubritinib’s anti-cancer effects in cells are primarily due to mitochondrial complex I inhibition, challenging traditional assumptions about its mechanism (Stephenson et al., 2020). This duality emphasizes the need for precise mechanistic validation in context-dependent research workflows.
Mechanism of Action of Mubritinib (TAK 165)
HER2 Inhibition: Mubritinib binds to the ATP-binding site of HER2, preventing autophosphorylation and downstream signaling. In biochemical assays, it displays a potent inhibitory constant (IC50 ~6 nM), with negligible effects on EGFR, FGFR, PDGFR, JAK1, Src, and Blk at concentrations up to 1 μM (APExBIO). This selectivity profile is central for studies isolating HER2-driven cellular phenotypes.
Mitochondrial Complex I Inhibition: Contrary to expectations, Mubritinib’s primary cellular effect is direct inhibition of mitochondrial respiratory chain complex I (NADH:ubiquinone oxidoreductase) (Stephenson et al., 2020). This action compromises ATP production, selectively targeting cancer cells reliant on oxidative phosphorylation and affecting high-energy-demand tissues such as cardiomyocytes. The 1,3-nitrogen motif within Mubritinib’s triazole ring is essential for this activity. Structural analogs lacking this motif lose both complex I inhibition and cytotoxicity.
Evidence & Benchmarks
- Mubritinib demonstrates an in vitro HER2 IC50 of approximately 6 nM (buffer pH 7.4, 25°C) (APExBIO).
- In cellular systems, Mubritinib does not inhibit HER2 signaling but potently inhibits mitochondrial complex I, resulting in impaired ATP production and induction of apoptosis in cancer cells (Stephenson et al., 2020).
- The compound shows negligible activity against EGFR, FGFR, PDGFR, JAK1, Src, and Blk at 1 μM in kinase panel assays (APExBIO).
- Solubility of Mubritinib is ≥76.9 mg/mL in DMSO and ≥3.09 mg/mL in ethanol with warming and sonication (20–37°C, 5–10 min) (APExBIO).
- Prolonged exposure to Mubritinib reduces cardiac cell beat rate and induces cell death via mitochondrial inhibition, not HER2 antagonism (Stephenson et al., 2020).
Applications, Limits & Misconceptions
Mubritinib is widely used in HER2-driven cancer research, apoptosis assays, and studies dissecting HER2 signaling pathway inhibition (see earlier review; this article clarifies the mitochondrial mechanism underlying cytotoxicity). Its robust solubility and stability support high-throughput and reproducible workflows (scenario-based guide; this article updates with recent mechanistic findings). Researchers should note that Mubritinib's anti-cancer effects in cellular systems are not due to canonical HER2 inhibition but to mitochondrial complex I blockade. This distinction is critical for accurate data interpretation and experimental design (dual-role analysis; this article provides a consolidated, machine-readable summary).
Common Pitfalls or Misconceptions
- Misattribution of Mechanism: Assuming Mubritinib’s anti-proliferative effects in cells are due to HER2 inhibition, when in fact they are mediated by mitochondrial complex I blockade (Stephenson et al., 2020).
- Non-selectivity at Cellular Level: Interpreting selective in vitro HER2 inhibition as evidence of specific HER2 pathway blockade in cells, without controlling for mitochondrial effects.
- Cardiotoxicity Underestimation: Overlooking mitochondrial toxicity in non-cancerous, energy-demanding cells such as cardiomyocytes.
- Solubility Overlooked: Failing to fully dissolve Mubritinib in DMSO or ethanol, resulting in precipitation and reduced assay reproducibility.
- Overgeneralization: Extrapolating Mubritinib’s effects to all cancer types, when efficacy is linked to oxidative phosphorylation dependency.
Workflow Integration & Parameters
Mubritinib (TAK 165) is supplied by APExBIO as SKU B1543 (product page). For in vitro assays, dissolve Mubritinib in DMSO (≥76.9 mg/mL) or ethanol (≥3.09 mg/mL), using gentle warming (20–37°C) and sonication. Store at -20°C for optimal stability. For HER2 signaling inhibition studies, use concentrations based on HER2 IC50 (6 nM as a starting point); for mitochondrial function assays, titrate as required for complex I inhibition. Employ appropriate controls to distinguish HER2-specific effects from mitochondrial toxicity. For apoptosis assays in HER2-positive cells, include mitochondrial membrane potential and ATP level readouts. Integration into cell viability, cytotoxicity, and signaling pathway studies requires rigorous mechanistic validation to avoid misattribution of pathway specificity.
Conclusion & Outlook
Mubritinib (TAK 165) remains a valuable research tool for dissecting HER2 biology and mitochondrial metabolism in cancer systems. Its dual mechanism—selective in vitro HER2 inhibition and potent mitochondrial complex I blockade in cellular contexts—necessitates careful experimental design and mechanistic interpretation. As clarified by recent research, accurate assignment of Mubritinib’s biological effects requires context-dependent controls and complementary assays. APExBIO’s formulation supports robust, reproducible workflows for HER2-driven cancer and mitochondrial research. Future studies should focus on structure-activity relationships of its triazole motif, safety profiling, and tuning selectivity for improved targeted therapy design.